Clifford A. Hudis, MD, and Maura N. Dickler, MD, of Memorial Sloan Kettering Cancer Center, discuss adding bevacizumab to letrozole as a first-line endocrine therapy for treatment of hormone receptor–positive advanced breast cancer (Abstract 501).
Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, and Areej El-Jawahri, MD, of Massachusetts General Hospital, discuss two important studies on early palliative care and the use of anamorelin in advanced NSCLC with cachexia.
Howard I. Scher, MD, of Memorial Sloan Kettering Cancer Center, discusses the updated criteria that will guide clinical trial design and conduct for therapeutics being tested in castration-resistant prostate cancer (Abstract 5000).
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).
For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show promise in multiple myeloma (Abstract LBA8512).
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).
